Patent application number | Description | Published |
20080287885 | Cylinder/Piston Unit Having a Non-Cylindrical Chamber - The invention relates to a cylinder/piston unit having a cylinder and a piston which is guided therein, wherein the cylinder and the piston enclose a chamber which can be filled at least for a time with an additive, and the cylinder has at least one exit element at its front end. Here, the cross section of the chamber or the cross section of the cylinder inner wall is increased at least in regions of the cylinder from the front to the back, wherein the cylinder end having the exit element is at the front. The piston has an elastic skirt at least in the front region, the front outer edge of said elastic skirt defining a cross-sectional area in the case of an unloaded piston, which is greater than an area which is defined by a contour line. The present invention develops a cylinder/piston unit which ensures simple and reliable handling and can be stored for a long time in the filled state, in a manner which is impervious to gas and moisture. | 11-20-2008 |
20090143466 | Isolation of Atraric Acid, Synthesis of Atraric Acid Derivatives, and Use of Atraric Acid and the Derivatives Thereof for the Treatment of Benign Prostatic Hyperplasia, Prostate Carcinoma and Spinobulbar Muscular Atrophy - A method for isolating atraric acid from biological material, atraric acid derivatives, the chemical synthesis thereof, and the use of atraric acid and the derivatives thereof for treating or producing a medicament for treating benign prostate hyperplasia, prostate carcinoma or spinobulbar muscular atrophy is provided. In addition, a basic substance for the development of other agents used for treating benign prostate hyperplasia, prostate carcinoma, or spinobulbar muscular atrophy is provided. | 06-04-2009 |
20090159553 | Closure system for containers - A closure system for containers used for storing or administering substances in the form of liquids, pastes or powders, which system in one embodiment includes a cap, provided with a through-hole, and a closure element, wherein the cap holds the closure element with a force fit and/or form fit on the container, in the area of the container opening that is to be closed, by means of a catch element present on the container. For this purpose, the end face which surrounds the container opening, and on which the closure element bears, comprises a depression. The closure element is a virus-proof, bacteria-proof and spore-proof film that lies on the end face and, at least in some areas, over the depression. The cap is then fitted in place, an elastomer ring or adhesive ring is arranged between the closure element and the depression and fills the depression. With the present invention, a closure system for containers is provided that allows the container to be securely closed permanently and in a virus-proof, bacteria-proof and spore-proof manner. | 06-25-2009 |
20090166978 | Cylinder/piston unit with at least three sealing elements - A cylinder/piston unit is disclosed for pre-fill, storage and release when desired of an active substance, such as a medicament. The cylinder/piston unit is provided with a cylinder and with a piston which is guided therein and which is sealed off in a sterile manner by a rubber seal, the cylinder and the piston enclosing a chamber that can be filled at least temporarily with active substance, and the cylinder having at least one discharge element at its front end. For this purpose, the piston resting in a rear position is sealed off relative to the cylinder in a sterile manner by a static front sealing element and by a static rear sealing element. Arranged spatially behind each static sealing element, there is a parking area for receiving the respective sealing element. When the piston is actuated, the individual static sealing elements are transferred from their respective sealing position into a parked position located in the parking area, and each sealing element in the parked position touches only the cylinder wall or only the piston wall. With the present invention, a cylinder/piston unit is developed which can be pre-filled and in which, despite a sterile sealing of the piston, only a slight force has to be applied in order to accelerate and/or move the piston. | 07-02-2009 |
20090202597 | Ache-Nmda Combination Wafer - Sheet-like pharmaceutical preparations based on hydrophilic polymers, which rapidly disintegrate upon contact with moisture and which are used to treat dementia-related illnesses The dosage form contains an active agent combination of at least two active agents which are suitable for the treatment of dementia (antidementia agents). The antidementia agents should be chosen from the group comprising acetyl cholinesterase inhibitors (AChE inhibitors) and NMDA antagonists (n-methyl-D-asparaginic acid antagonists). The use of such an active agent combination for producing an orally administrable pharmaceutical product for the treatment of dementia-related illnesses such as Alzheimer's disease, as well as a procedure for the symptomatic treatment of Alzheimer's disease by the oral administration of one of the above pharmaceutical products is also provided. | 08-13-2009 |
20090203670 | Combination Antidepressants Wafer - A sheet-like pharmaceutical preparation (dosage form) that quickly disintegrates on contact with moisture, based on hydrophilic polymers for the release of at least one active agent. The dosage form contains an active agent combination for treating depression, and at least one active agent selected from the antidepressant group of drugs. In addition, the use of such a combination of active agents for the production of an orally administrable pharmaceutical product for the treatment of depression, and the therapeutic treatment of depression by oral administration of one of the named pharmaceutical preparations, is provided. | 08-13-2009 |
20090254036 | Single-use injector with at least one draw hook - A single-use injector is disclosed comprising a housing ( | 10-08-2009 |
20090274732 | Type-2 Diabetes Combination Wafer - Rapidly disintegrating oral dosage forms for the application of active agent combinations for diabetes therapy. The dosage forms contain at least two active agents suitable for treating type-2 diabetes. The antidiabetic active agents are selected from the group comprising sulfonylureas, glitazones, glinides, biguanides, and absorption-delaying agents. The use of the active agent combination to produce an oral dosage form for the treatment of diabetes, a method for the therapeutic treatment of diabetes, and a method for the production of a sheet-like dosage form are also disclosed. | 11-05-2009 |
20100015315 | EDIBLE FILM-SHAPED PREPARATION WITH COLA TASTE - The invention relates to edible film-shaped cola-flavoured preparations which disintegrate quickly and without leaving a residue when coming in contact with moisture. | 01-21-2010 |
20100047322 | Combination antihypertensive wafer - Sheet-like dosage forms that quickly dissolve or disintegrate in an aqueous environment, for the application of active agent combinations for the treatment of hypertension. The dosage forms contain at least two active agents that are suitable for the treatment of hypertension. The antihypertensive agents are selected from the group that encompasses beta receptor blockers, alpha receptor blockers, calcium antagonists, ACE inhibitors, AT | 02-25-2010 |
20100233244 | Smoking Withdrawal Combination Wafer - The present invention relates to a quickly decomposing oral drug preparation, for the application of active ingredient combinations for smoking withdrawal, which contains nicotine, a nicotine salt, a nicotine derivative, or a substance that reacts to nicotine, in combination with another active ingredient, and the use of such a drug preparation for the treatment of smoking withdrawal, and the use of nicotine, and/or nicotine salts or derivatives, for the production of medications for the treatment of smoking withdrawal. The active ingredient that is to be administered, in combination, for this purpose is a centrally active ingredient, preferably an antidepressant for the fighting of psychic dependency in terms of a smoking withdrawal therapy. The administration of the active ingredient combination to the patient should be handled in a simple and reliable way and should exclude side effects to a large extent. | 09-16-2010 |
20110159076 | Autodestructive Transdermal Therapeutic System - The invention relates to a transdermal therapeutic system (TTS), preferably in the form of a transdermal plaster, that contains an active substance and an agent which can destroy the active substance. The TTS further includes a means of bringing the active substance, e.g. buprenorphine, and the agent, e.g. potassium permanganate, into contact when the TTS is removed from the skin of the patient, thereby causing the active substance to be destroyed. | 06-30-2011 |
20110268800 | Unsaturated fatty acids as thrombin inhibitors - A preparation having at least one unsaturated fatty acid and the use of at least one unsaturated fatty acid having a chain length of 18 or 20 carbon atoms and of plant drugs containing the unsaturated fatty acid as a free fatty acid or a fatty acid radical of a triglyceride. The fatty acid has a chain length of 18 carbon atoms which are provided with 1 to 3 double bonds and the fatty acid has a chain length of 20 carbon atoms which are provided with 1 to 4 double bonds. The double bond or one of the double bonds are located in position 9 or 11 of the carbon chain. The unsaturated fatty acid is supplied in the all-cis configuration. The at least one unsaturated fatty acid prevents and/or treats or is used for producing a preparation for preventing and/or treating thrombosis and thromboembolic diseases. | 11-03-2011 |
20110311593 | N-HYDROXYLATED AMIDINE-, GUANIDINE- AND/OR AMINOHYDRAZONE-TYPE PRODRUGS FOR APPLICATION ON THE SKIN - The invention relates to N-hydroxylated amidines, guanidines and aminohydrazones for application on the skin. In particular, the invention relates to transdermal therapeutic systems containing N-hydroxylated amidines, guanidines and aminohydrazones as a prodrug, and to methods for producing and using such systems. | 12-22-2011 |
20120273491 | CLOSURE SYSTEM FOR CONTAINERS - A closure system for containers used for storing or administering substances in the form of liquids, pastes or powders that allows the container to be securely closed permanently and in a virus-proof, bacteria-proof and spore-proof manner. The container having an opening that is to be closed, a cap provided with a through-hole, the cap including a substantially cylindrical securing area, and a closure element for sealing the opening. The container includes an end face which surrounds the opening and on which the closure element bears. The closure element comprises a virus-proof, bacteria-proof and spore-proof film, and the cap comprises at least one closed, elastic sealing lip bearing resiliently in a direction towards the closure element in the operative position. | 11-01-2012 |
20140272069 | Edible film-shaped preparation with cola taste - The invention relates to edible film-shaped cola-flavored preparations which disintegrate quickly and without leaving a residue when coming in contact with moisture. In advantageous embodiments, edible, water-soluble, film-shaped preparations containing cola flavoring are provided that contain hydroxypropylated pea starch and hydroxypropylated tapioca starch as a film-forming polymer, or contains such a polymer in combination with further film-forming polymers. | 09-18-2014 |
20140378917 | TRANSDERMAL THERAPEUTIC SYSTEM WITH A LOW TENDENCY TO SPONTANEOUSLY CRYSTALLIZE - The present invention provides transdermal therapeutic systems for dispensing a pharmaceutical product, in particular a pharmaceutical product with a low tendency to spontaneously crystallize. The matrix layer or at least one of the matrix layers in said systems contains a silicone hot-melt adhesive, a pharmaceutical product, and particles made of crosslinked polyvinylpyrrolidone. The invention also relates to a method for producing said transdermal therapeutic systems. | 12-25-2014 |